Olaparib, a PARP inhibitor, has received FDA approval for the treatment and maintenance of several cancers, particularly those with a germline BRCA1 or BRCA2 mutation, including HER2-negative metastatic breast cancer [34,35,36,37]. Here, BRCA1 is linked to cancer.